RecruitingPhase 4NCT06676384

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Christian Medical College, Vellore, India
Principal Investigator
Jonathan Barratt, PhD, FRCP
University of Leicester
Intervention
Oral prednisolone and SoC(drug)
Enrollment
585 enrolled
Eligibility
18-65 years · All sexes
Timeline
2025 – 2029

Study locations (12)

Collaborators

Medical Research Council · India Alliance

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06676384 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials